# A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer

> **NCT06410534** · PHASE2 · WITHDRAWN · sponsor: **National Cancer Institute (NCI)**

## Conditions studied

- Colorectal Cancer
- Gastroesophageal Cancer

## Interventions

- **DRUG:** nivolumab
- **DRUG:** ipilimumab

## Key facts

- **NCT ID:** NCT06410534
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-09-09
- **Primary completion:** 2025-09-09
- **Final completion:** 2025-09-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** PI left NIH.
- **Last updated:** 2025-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06410534

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06410534, "A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06410534. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*